- Home
- NRXS vs GOVX Comparison
NRXS vs GOVX Comparison
Compare NRXS & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- GOVX
- Stock Information
- Founded
- NRXS 2011
- GOVX 2001
- Country
- NRXS United States
- GOVX United States
- Employees
- NRXS N/A
- GOVX N/A
- Industry
- NRXS
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- GOVX Health Care
- Exchange
- NRXS Nasdaq
- GOVX Nasdaq
- Market Cap
- NRXS 13.0M
- GOVX 15.5M
- IPO Year
- NRXS 2023
- GOVX N/A
- Fundamental
- Price
- NRXS $2.49
- GOVX $0.95
- Analyst Decision
- NRXS Strong Buy
- GOVX Strong Buy
- Analyst Count
- NRXS 1
- GOVX 5
- Target Price
- NRXS $7.00
- GOVX $12.40
- AVG Volume (30 Days)
- NRXS 155.9K
- GOVX 1.5M
- Earning Date
- NRXS 08-08-2025
- GOVX 08-05-2025
- Dividend Yield
- NRXS N/A
- GOVX N/A
- EPS Growth
- NRXS N/A
- GOVX N/A
- EPS
- NRXS N/A
- GOVX N/A
- Revenue
- NRXS $2,934,945.00
- GOVX $5,591,576.00
- Revenue This Year
- NRXS $138,883.78
- GOVX N/A
- Revenue Next Year
- NRXS $118.59
- GOVX N/A
- P/E Ratio
- NRXS N/A
- GOVX N/A
- Revenue Growth
- NRXS 27.52
- GOVX N/A
- 52 Week Low
- NRXS $1.33
- GOVX $0.73
- 52 Week High
- NRXS $6.20
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- NRXS 49.91
- GOVX 46.22
- Support Level
- NRXS $2.33
- GOVX $0.85
- Resistance Level
- NRXS $2.67
- GOVX $1.39
- Average True Range (ATR)
- NRXS 0.17
- GOVX 0.15
- MACD
- NRXS -0.01
- GOVX -0.02
- Stochastic Oscillator
- NRXS 46.43
- GOVX 18.52
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.